As the majority of sell-side analysis rushed in to defend Valeant Pharmaceuticals yesterday and early this morning, there is one point of consistency in a key component of the case that is being overlooked. The odd question of how the sales cycle worked and how a relatively small pharmacy was able to rack up such debt with Valeant has remained on the sidelines. All the positive research notes come as Valeant stock is down near 18 percent in early morning trade, and Pershing Square losing nearly $440 million in investor capital, Canadian regulators are asking serious questions as the market in credit…
Sell-Side Analysts Mostly Express Undying Love For Valeant As Regulators Express Doubts
Mark Melin
Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.